Cargando…
Hugan Qingzhi medication ameliorates free fatty acid-induced L02 hepatocyte endoplasmic reticulum stress by regulating the activation of PKC-δ
BACKGROUND: Previous studies have found that Hugan Qingzhi tablet (HQT) has significant lipid-lowering and antioxidant effects on non-alcoholic fatty liver disease (NAFLD). Moreover, the results of proteomic analysis confirmed that various proteins in endoplasmic reticulum stress (ERS) pathway were...
Autores principales: | Yang, Miaoting, Chen, Zhijuan, Xiang, Shijian, Xia, Fan, Tang, Waijiao, Yao, Xiaorui, Zhou, Benjie |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7730760/ https://www.ncbi.nlm.nih.gov/pubmed/33308192 http://dx.doi.org/10.1186/s12906-020-03164-3 |
Ejemplares similares
-
Data for iTRAQ-based quantification of the effect of HuganQingzhi on non-alcoholic fatty liver disease in rats
por: Yao, Xiaorui, et al.
Publicado: (2017) -
Modulation of the Gut Microbiota in Rats by Hugan Qingzhi Tablets during the Treatment of High-Fat-Diet-Induced Nonalcoholic Fatty Liver Disease
por: Tang, Waijiao, et al.
Publicado: (2018) -
Isobaric Tags for Relative and Absolute Quantitation (iTRAQ)-Based Proteomic Analysis of Hugan Qingzhi and Its Protective Properties against Free Fatty Acid-Induced L02 Hepatocyte Injury
por: Xia, Fan, et al.
Publicado: (2017) -
Hugan Qingzhi Exerts Anti-Inflammatory Effects in a Rat Model of Nonalcoholic Fatty Liver Disease
por: Tang, WaiJiao, et al.
Publicado: (2015) -
Discovery of Quality Markers in Hugan Qingzhi Formula by Integrating a Lipid-Lowering Bioassay with UHPLC-QQQ-MS/MS
por: He, Fan, et al.
Publicado: (2020)